Kevin J. Hamblett

2.3k total citations · 1 hit paper
20 papers, 1.8k citations indexed

About

Kevin J. Hamblett is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Kevin J. Hamblett has authored 20 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 15 papers in Radiology, Nuclear Medicine and Imaging and 6 papers in Molecular Biology. Recurrent topics in Kevin J. Hamblett's work include HER2/EGFR in Cancer Research (15 papers), Monoclonal and Polyclonal Antibodies Research (15 papers) and Lymphoma Diagnosis and Treatment (6 papers). Kevin J. Hamblett is often cited by papers focused on HER2/EGFR in Cancer Research (15 papers), Monoclonal and Polyclonal Antibodies Research (15 papers) and Lymphoma Diagnosis and Treatment (6 papers). Kevin J. Hamblett collaborates with scholars based in United States and France. Kevin J. Hamblett's co-authors include Charles G. Cerveny, Michael Sun, Peter D. Senter, Damon L. Meyer, Kim M. Kissler, Dana F. Chace, Roger F. Zabinski, Joseph A. Francisco, Stephen C. Alley and Nathan C. Ihle and has published in prestigious journals such as Blood, Cancer Research and Clinical Cancer Research.

In The Last Decade

Kevin J. Hamblett

18 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate

2004 909 citations Kevin J. Hamblett, Peter D. Senter et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Kevin J. Hamblett

Since Specialization

Citations

This map shows the geographic impact of Kevin J. Hamblett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin J. Hamblett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin J. Hamblett more than expected).

Fields of papers citing papers by Kevin J. Hamblett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin J. Hamblett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin J. Hamblett. The network helps show where Kevin J. Hamblett may publish in the future.

Co-authorship network of co-authors of Kevin J. Hamblett

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin J. Hamblett. A scholar is included among the top collaborators of Kevin J. Hamblett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin J. Hamblett. Kevin J. Hamblett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract C132: SGN-35T: A novel CD30-directed antibody-drug conjugate for the treatment of lymphomas 2023 ·Molecular Cancer Therapeutics ·Kevin J. Hamblett, (unknown), Roma Yumul, Yufei Chen, John H. Kwon, Jessica K. Simmons, Clark M. Henderson, Hao Sun, Jason Schrum, Andrea R. Lim, (unknown), Melissa Conerly, Astrid Clarke	2
2	SGN-35C: A Novel CD30-Directed Antibody-Drug Conjugate for the Treatment of Lymphomas 2023 ·Blood ·Kevin J. Hamblett, Julia H. Cochran, (unknown), (unknown), Roma Yumul, Jessica K. Simmons, Ivan J. Stone, (unknown), Jason Schrum, Andrea Lim, Astrid Clarke	3
3	Abstract 2633: Zanidatamab zovodotin (ZW49) induces hallmarks of immunogenic cell death and is active in patient-derived xenograft models of gastric cancer 2023 ·Cancer Research ·(unknown), (unknown), Kevin J. Hamblett, Nichole Escalante	10
4	A novel drug conjugate platform: Redefining the therapeutic window for ADCs 2018 ·Annals of Oncology ·John S. Babcook, R. H. Davies, (unknown), Justin Rich, (unknown), (unknown), Geoffrey C. Winters, (unknown), (unknown), Kevin J. Hamblett	1
5	Abstract 3914: ZW49, a HER2-targeted biparatopic antibody-drug conjugate for the treatment of HER2-expressing cancers 2018 ·Cancer Research ·Kevin J. Hamblett, (unknown), (unknown), (unknown), R. H. Davies, Grant Wickman, Andrea Hernández, (unknown), (unknown), Geoffrey C. Winters, Jamie R. Rich, John S. Babcook	37
6	Abstract 61: Zymelink drug conjugate platform: redefining the therapeutic window for ADCs 2017 ·Cancer Research ·(unknown), John S. Babcook, (unknown), (unknown), (unknown), Andrea Hernández, (unknown), (unknown), Kevin J. Hamblett, R. H. Davies	2
7	Altering Antibody–Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability 2016 ·Molecular Pharmaceutics ·Kevin J. Hamblett, Tiep Le, Brooke M. Rock, Dan A. Rock, Sophia Siu, (unknown), Kip P. Conner, Robert R. Milburn, Jason O’Neill, Mark Tometsko, William C. Fanslow	31
8	SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm 2015 ·Cancer Research ·Kevin J. Hamblett, Allison P. Jacob, Jesse L. Gurgel, Mark Tometsko, Brooke M. Rock, Sonal Patel, Robert R. Milburn, Sophia Siu, Seamus P. Ragan, Dan A. Rock, Christopher J. Borths, Jason O’Neill, Wesley Chang, Margaret F. Weidner, Matthew M. Bio, Kim Quon, William C. Fanslow	90
9	AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma 2015 ·Molecular Cancer Therapeutics ·Kevin J. Hamblett, Carl J. Kozlosky, Sophia Siu, Wesley Chang, Hua Liu, Ian N. Foltz, Esther S. Trueblood, David Meininger, Taruna Arora, (unknown), Steven Vonderfecht, Qing Chen, John S. Hill, William C. Fanslow	82
10	Intracellular Catabolism of an Antibody Drug Conjugate with a Noncleavable Linker 2015 ·Drug Metabolism and Disposition ·Brooke M. Rock, Mark Tometsko, Sonal Patel, Kevin J. Hamblett, William C. Fanslow, Dan A. Rock	20
11	Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment 2006 ·Protein Engineering Design and Selection ·Charlotte F. McDonagh, Eileen Turcott, Lori Westendorf, (unknown), Stephen C. Alley, (unknown), Jamie B. Andreyka, Ivan J. Stone, Kevin J. Hamblett, J A Francisco, Paul Carter	182
12	Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics 2005 ·Leukemia ·Charles G. Cerveny, (unknown), (unknown), (unknown), Kevin J. Hamblett, Lori Westendorf, (unknown), Joseph M. Petroziello, J A Francisco, Alan F. Wahl	45
13	Reduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides 2005 ·Bioconjugate Chemistry ·Michael Sun, (unknown), Charles G. Cerveny, Kevin J. Hamblett, Richard S. Blackmore, Michael Torgov, (unknown), Nathan C. Ihle, Peter D. Senter, Stephen C. Alley	294
14	SGN-35, an Anti-CD30 Antibody-Drug Conjugate, Exhibits Potent Antitumor Activity for the Treatment of CD30+ Malignancies. 2005 ·Blood ·Kevin J. Hamblett, Jeremy Barton, Charles G. Cerveny, Jamie B. Andreyka, Kim M. Kissler, Nicole M. Okeley, Ivan J. Stone, May Kung Sutherland, Michael Sun, Peter D. Senter, Alan F. Wahl, Nathan C. Ihle	13
15	Immunoconjugates comprised of drugs with impaired cellular permeability: A new approach to targeted therapy 2004 ·Cancer Research ·Peter D. Senter, (unknown), Brian A. Mendelsohn, Brian E. Toki, (unknown), Damon L. Meyer, Kevin J. Hamblett, Joseph A. Francisco, Charles G. Cerveny, Alan F. Wahl	2
16	Effect of drug loading on the pharmacology, pharmacokinetics, and toxicity of an anti-CD30 antibody-drug conjugate 2004 ·Cancer Research ·Kevin J. Hamblett, Damon L. Meyer, Dana F. Chace, (unknown), Charles G. Cerveny, Michael Sun, Peter D. Senter, Joseph A. Francisco	0
17	The Anti-CD30 Monoclonal Antibody SGN-30 Inhibits Hodgkins Disease Growth and Sensitizes Cells to Established Chemotherapeutics. 2004 ·Blood ·Charles G. Cerveny, Che‐Leung Law, (unknown), (unknown), Kevin J. Hamblett, Lori Westendorf, (unknown), Joseph M. Petroziello, Joseph A. Francisco, Alan F. Wahl	3
18	Role of Biotin-Binding Affinity in Streptavidin-Based Pretargeted Radioimmunotherapy of Lymphoma 2004 ·Bioconjugate Chemistry ·Kevin J. Hamblett, Oliver W. Press, Damon L. Meyer, Don K. Hamlin, Don B. Axworthy, D. Scott Wilbur, Patrick S. Stayton	27
19	Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate breakdown → 2004 ·Clinical Cancer Research ·Kevin J. Hamblett, Peter D. Senter, Dana F. Chace, Michael Sun, (unknown), Charles G. Cerveny, Kim M. Kissler, (unknown), (unknown), Roger F. Zabinski, Damon L. Meyer, Joseph A. Francisco	909
20	A Streptavidin−Biotin Binding System That Minimizes Blocking by Endogenous Biotin 2002 ·Bioconjugate Chemistry ·Kevin J. Hamblett, (unknown), Don K. Hamlin, Ming‐Kuan Chyan, David E. Hyre, Oliver W. Press, D. Scott Wilbur, Patrick S. Stayton	53

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact